Explore the journeys of women leaders of color
The Women of Color Leadership Series, part of Katie Leadership Impact, brings high-profile leaders to share their stories of the learning and inspirational opportunities that paved their paths to leadership. The world’s need for effective women leaders from all racial and socio-economical walks of life has never been greater. Yet the representation of women — particularly women of color — in corporate leadership roles continues to suffer underrepresentation among companies. The Women of Color Leadership Series connects students with the leaders who represent the brightest hopes for meaningful change in our world, inspiring the future leaders who will go forth to transform it.
Dr. Tamar Rodney
Johns Hopkins University, School of Nursing
November 9, 2022
Whitby Hall room 122
President's Dining Room, Coeur de Catherine
About Dr. Rodney
Dr. Tamar Rodney is a board-certified psychiatric nurse practitioner. Her research identifies biomarkers for PTSD in individuals with a history of traumatic brain injury and addresses coping issues for students with mental health needs. With professional expertise in trauma and psychiatry, she maintains a clinical practice in Baltimore serving families recovering from substance use.
Dr. Kizzmekia S. Corbett, PhD, is an assistant professor in the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health. She also holds an appointment at the Harvard Radcliffe Institute as the Shutzer Assistant Professor. She leads a new lab to study and understand the interface between hosts’ immune systems and viruses that cause respiratory disease, with the goal of informing development of novel and potentially universal vaccines.
Dr. Corbett uses her viral immunology expertise to propel novel vaccine development for pandemic preparedness, including mRNA-1273, a leading vaccine against SARS-CoV-2. The vaccine concept incorporated in mRNA-1273 was designed by Dr. Corbett's NIH team from viral sequence and rapidly deployed to industry partner, Moderna, Inc., for Phase 1 clinical trial, which unprecedently began only 66 days from viral sequence release. mRNA-1273 was shown to be 94.1% effective in Phase 3 trial and is authorized for use in multiple countries. Alongside mRNA-1273, Dr. Corbett boasts a patent portfolio which also includes universal coronavirus and influenza vaccine concepts and novel therapeutic antibodies.
In all, she has over 15 years of experience studying dengue virus, respiratory syncytial virus, influenza virus, and coronaviruses, garnering several prestigious awards, such as the Benjamin Franklin Next Gen Award and the Salzman Memorial Award in Virology. Combining her research goals with her knack for mentorship, Dr. Corbett invests much of her time in underserved communities as an advocator of STEM education and vaccine awareness.
She received a B.S. in Biological Sciences, with a secondary major in Sociology, in 2008 from the University of Maryland–Baltimore County, where she was a Meyerhoff Scholar and an NIH undergraduate scholar. She then enrolled at University of North Carolina at Chapel Hill, where she obtained her Ph.D. in Microbiology and Immunology in 2014.
Masks are required at The O'Shaughnessy. Proof of full COVID-19 vaccination is required for admittance or a negative non-home COVID test within 72 hours of the event. Full information
ASL interpretation will be provided.
Contact Namibia Little, Katie Leadership Impact program director, with questions at email@example.com or 651-690-6190.
This series is sponsored by Katie Leadership Impact.
Katie Leadership Impact is an undergraduate program that fosters leadership capabilities through coursework, applied learning, professional activities, and student support. This program is possible thanks to a generous grant from The Manitou Fund.